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LETTER TO THE EDITOR
Failure to Detect Differences in Proliferation Status of Nevi
from CDKN2A Mutation Carriers and Non-Carriers
To the Editor,
Approximately 40% of familial melanoma is caused by a mutation
in cyclin-dependent kinase inhibitor A (CDKN2A2, p16)
(Piepkorn, 2000), a tumor suppressor that acts by regulating the
cell cycle via the retinoblastoma (Rb) tumor suppressor pathway
(Ruas and Peters, 1998). Although the cellular and molecular
functions of CDKN2A have been studied extensively, the precise
mechanism by which a mutation in this gene leads to increased
susceptibility to melanoma remains unclear (Scherr, 2001). One
possibility is that loss of CDKN2A activity results in cell-cycle
dysregulation and increased melanocytic proliferation. The clinical
presentation of CDKN2A mutation carriers who have increased
numbers and size of nevi (dysplastic nevus syndrome) (Meyer et al,
1992; Cannon-Albright et al, 1994; Newton-Bishop et al, 2000) is
consistent with this hypothesis. Furthermore, the inherent genomic
instability of rapidly proliferating cells would help to explain the
underlying predisposition toward melanoma in these families.
Proliferation studies of melanocytic lesions have been done utilizing
both Ki-67 (Smolle et al, 1989; Moretti et al, 1990; Rudolph et al,
1997; Rudolph et al, 1998; Tran et al, 1998; Grossman et al, 1999;
Kaleem et al, 2000) and topoisomerase II alpha (topo II) ( Lynch et
al, 1997; Mu et al, 2000). For studies involving common and
dysplastic nevi, the proliferative indices by Ki-67 immunostaining
are very low (<1%); however, the proliferation index for melanoma
in situ, primary melanoma, and metastatic melanoma, is much
higher (6.3%±16.0%, Fig 1), suggesting a relationship between the
degree of proliferation and the aggressiveness of the tumor. The
relationship between the proliferation status of melanocytic lesions
and CDKN2A carrier status has never been examined. This study
tests the hypothesis that carriage of a CDKN2A mutation results in
a higher proliferative status in nevi taken from carriers of the
mutation relative to noncarrier family member controls. The Utah
melanoma kindred 1771 that was used in this study was one of the
large families originally utilized to establish the melanoma suscep-
tibility locus on chromosome 9p21 (Cannon-Albright et al, 1992)
and later to con®rm the relevance of the CDKN2A mutation in
familial melanoma (Kamb et al, 1994). Of the 36 kindred members
evaluated in this study, 12 were identi®ed as CDKN2A (V126D)
mutation carriers and 24 as noncarriers by haplotype and sequence
analysis. The proliferation status in this study was determined by
assignment of a topo II index to nevi from K1771 family members
that carried or did not carry the CDKN2A mutation. Topo II is a
well-established marker of cellular proliferation and has been used
to establish proliferation indices in malignant and nonmalignant
tissues and is analogous to Ki67/MIB1 (Rohr and Holden, 1999;
Willman and Holden, 2000). Like Ki67/MIB1, topo II is
selectively expressed in the S, G2, and M phases of the cell cycle,
but unlike Ki67/MIB1 whose function is unknown, topo II is well
established as an essential enzyme for DNA replication (Holden,
1999). Because of these features, topo II was selected as the best
representative marker of cellular proliferation. Topo II immuno-
staining was performed on 66 nevi removed from the 36 members
of the K1771 kindred. Tissue sections were stained with
hematoxylin and eosin and immunostained for topo II protein
according to standard protocol (Lynch et al, 1997; Rohr and
Holden, 1999; Willman and Holden, 2000). Each slide was
evaluated in blinded fashion by a pathologist (SRF) who rendered a
diagnosis for each nevus according to a slightly modi®ed categorical
rating scheme as previously published (Piepkorn, 1990), ranging
from a banal nevus (category 1) to melanoma in situ (category 5).
Category 4 nevi are those with architectural disorder (dysplastic
nevi). Table I shows the number and classi®cation of nevi in each
category. To calculate the topo II index, up to 500 nevus cells were
counted from the area of maximal nevus cell staining in both the
junctional and/or the dermal compartment: [(number positive/up
to 500) 3 100]. Results were evaluated in conjunction with the
kindred members' mutation status. One of the biopsies from a
mutation carrier was melanoma in situ (category 5) and was
excluded from the data analysis (topo II index 7.2%).
Despite the observations that nevi from melanoma-prone
kindreds are larger and more numerous, we were unable to
identify differences in proliferative activity of nevi from the carrier
and noncarrier groups, irrespective of the category of nevus, or
whether the nevus was situated at the dermo±epidermal junction,
dermis, or was compound (Table II). The topo II index for the
single melanoma in situ lesion was considerably higher than any of
the nevi. As can be seen in Fig 1, these data are comparable with
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Figure 1. Average topo II proliferation index among nevi (N) in
CDKN2A carriers and noncarriers. One melanoma in situ (MIS)
from a carrier showed a topo II index of 7.2%. The right half of this
®gure shows the averages or weighted averages of the proliferation
indices from nevi (Smolle et al, 1989; Moretti et al, 1990; Rudolph et al,
1997) melanoma in situ (Rudolph et al, 1997), primary melanomas (PM;
Smolle et al 1989; Moretti et al, 1990; Rudolph et al, 1998; Grossman et
al, 1999), and metastatic melanomas (MM; Smolle et al 1989; Moretti et
al, 1990; Grossman et al, 1999). These proliferation indices were
determined by Ki-67 immunostaining.
previous proliferation studies of nevi and melanoma in situ utilizing
Ki-67.
In summary, whereas the cellular proliferation index of these
nevi as determined by topo II immunostaining are in keeping with
the reports of other authors, the hypothesis that nevi from
CDKN2A mutation carriers would be in a higher proliferative
state than nevi from noncarriers could not be substantiated based on
the results from this study. Although this technique was able to
detect large differences in proliferation rates between nevi and
melanoma in situ, among nevi there may be very small differences
in proliferative capacity undetectable by topo II staining between
carriers and noncarriers. These small differences, over time, could
account for differences in phenotype. It also is possible that
CDKN2A-mediated increases in cellular proliferation only occur in
response to stimuli (such as hormonal stimulation during puberty or
ultraviolet light exposure) that were not present at the time of
biopsy of these lesions. Another testable hypothesis is that decreased
CDKN2A activity leads to decreased cellular senescence rather than
increased proliferation, ultimately leading to the dysplastic nevus
phenotype. Finally, it is possible that dysplastic nevi may be similar
to neuro®bromas (Sawada et al, 1996), requiring a second mutation
in CDKN2A before a signi®cant change in cellular function occurs.
Further investigation is underway to evaluate the role of germline
CDKN2A mutation in the increased size and number of nevi and
the relationship of mutation status with the increased susceptibility
to melanoma.
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Table II. Average topo II index of nevi from mutation
carriers and noncarriers
# nevi Average/SD (%) Range (%) P value
Total
Carrier 24 0.19 + 0.20 0±0.6 0.13
Non-carrier 40 0.27 + 0.28 0±1.2
Junctional
Carrier 16 0.31 + 0.30 0±0.9 0.52
Non-carrier 25 0.34 + 0.30 0±1.0
Dermal
Carrier 19 0.10 + 0.20 0±0.6 0.12
Non-carrier 35 0.21 + 0.31 0±1.4
Table I. Number of biopsies and categorization of nevi by carrier status
Mutation status
# Family
members Biopsies Category 1 Category 2 Category 3 Category 4 Category 5 (MIS)
Carrier 12 25 7 28% 0 1 (4%) 16 (64%) 1 (4%)
Non-carrier 24 41 17 (46%) 1 (2%) 1 (2%) 22 (50%) 0
Total 36 66 24 (36%) 1 (1.5%) 2 (3%) 38 (58%) 1 (1.5%)
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